

## ***Streptococcus pneumoniae*, Strain STREP2**

**Catalog No. NR-31700**

**For research use only. Not for human use.**

### **Contributor and Manufacturer:**

Moon H. Nahm, M.D., Professor, Department of Pathology, University of Alabama at Birmingham

### **Product Description:**

Bacteria Classification: *Streptococcaceae*, *Streptococcus*

Species: *Streptococcus pneumoniae*

Strain: STREP2

Source: *Streptococcus pneumoniae* (*S. pneumoniae*), strain STREP2 was derived from a human wild-type *S. pneumoniae* strain by natural selection using increasing concentrations of streptomycin.<sup>1</sup>

*S. pneumoniae* is a Gram-positive,  $\alpha$ -hemolytic diplococcal aerotolerant anaerobe that is a major cause of pneumonia, bacterial meningitis and otitis media. *S. pneumoniae* has a polysaccharide capsule that acts as a virulence factor for the organism. There are over ninety different capsular types of *S. pneumoniae* which differ in virulence, prevalence, and extent of drug resistance.<sup>2</sup>

### **Material Provided:**

Each vial contains approximately 1.8 mL of bacterial culture in Todd-Hewitt broth containing 0.5% (w/v) yeast extract and 15% glycerol.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

### **Packaging/Storage:**

NR-31700 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

### **Citation:**

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: *Streptococcus pneumoniae*, Strain STREP2, NR-31700."

### **Biosafety Level: 2**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see <http://www.cdc.gov/biosafety/publications/bmbl5/index.htm>.

### **Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither the ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

### **Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

### **References:**

1. Robert L. Burton, personal communication
2. Burton, R. L. and M. H. Nahm. "Development and Validation of a Fourfold Multiplexed Opsonization Assay (MOPA4) for Pneumococcal Antibodies." Clin. Vaccine Immunol. 13 (2006): 1004-1009. PubMed: 16960111.

ATCC® is a trademark of the American Type Culture Collection.

